Development of an MCM5 ELISA test for oesophageal cancer
Research type
Research Study
Full title
FEASIBILITY STUDY OF THE USE OF ARQUER’S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF OESOPHAGEAL CANCER USING GASTRIC ASPIRATES
IRAS ID
214612
Contact name
Jacqueline Stockley
Contact email
Sponsor organisation
Arquer Diagnostics Ltd
Duration of Study in the UK
0 years, 9 months, 30 days
Research summary
Arquer's intention is to develop a simple test that will help clinicians to make an assessment of the likelihood of patients having oesophageal cancer and detecting early stage cancer which may currently be missed. The purpose of this study is to establish if MCM5, a protein expressed in cancer cells, is detectable in patients with Oesophageal Cancer. Gastric aspirates will be collected from patients with advanced disease, early stage disease, non dysplastic Barrett's oesophagus and normal controls, and the presence of MCM5 will be determined using Arquer Diagnostic’s MCM5 ELISA. Some clinical information on the presence and stage/severity of disease would also be collected. The results of the testing by Arquer will in no way influence the treatment of the patient, but will provide Arquer with proof of principle data prior to full scale clinical performance evaluations. This will greatly improve Arquer's chances of success in developing clinically useful tests for future diagnosis of oesophageal cancer.
REC name
London - Riverside Research Ethics Committee
REC reference
17/LO/0436
Date of REC Opinion
18 Apr 2017
REC opinion
Further Information Favourable Opinion